MA62148B1 - Inhibiteur de magl - Google Patents
Inhibiteur de maglInfo
- Publication number
- MA62148B1 MA62148B1 MA62148A MA62148A MA62148B1 MA 62148 B1 MA62148 B1 MA 62148B1 MA 62148 A MA62148 A MA 62148A MA 62148 A MA62148 A MA 62148A MA 62148 B1 MA62148 B1 MA 62148B1
- Authority
- MA
- Morocco
- Prior art keywords
- compounds
- magl
- compositions
- magl inhibitor
- useful
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6558—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system
- C07F9/65583—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing at least two different or differently substituted hetero rings neither condensed among themselves nor condensed with a common carbocyclic ring or ring system each of the hetero rings containing nitrogen as ring hetero atom
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pain & Pain Management (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Rheumatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063113662P | 2020-11-13 | 2020-11-13 | |
| EP21811018.7A EP4244208B1 (en) | 2020-11-13 | 2021-11-12 | A magl inhibitor |
| PCT/EP2021/081522 WO2022101412A1 (en) | 2020-11-13 | 2021-11-12 | A magl inhibitor |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA62148B1 true MA62148B1 (fr) | 2025-05-30 |
Family
ID=78709459
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA62148A MA62148B1 (fr) | 2020-11-13 | 2021-11-12 | Inhibiteur de magl |
Country Status (33)
| Country | Link |
|---|---|
| US (2) | US11434222B2 (pl) |
| EP (2) | EP4244208B1 (pl) |
| JP (1) | JP7856644B2 (pl) |
| KR (1) | KR20230107225A (pl) |
| CN (2) | CN121824488A (pl) |
| AR (1) | AR124057A1 (pl) |
| AU (1) | AU2021379081A1 (pl) |
| CA (1) | CA3196119A1 (pl) |
| CL (1) | CL2023001339A1 (pl) |
| CO (1) | CO2023004649A2 (pl) |
| CR (1) | CR20230203A (pl) |
| DK (1) | DK4244208T3 (pl) |
| DO (1) | DOP2023000086A (pl) |
| ES (1) | ES3025484T3 (pl) |
| FI (1) | FI4244208T3 (pl) |
| GE (2) | GEAP202516246A (pl) |
| HR (1) | HRP20250644T1 (pl) |
| HU (1) | HUE071543T2 (pl) |
| IL (1) | IL301818B1 (pl) |
| JO (1) | JOP20230091A1 (pl) |
| LT (1) | LT4244208T (pl) |
| MA (1) | MA62148B1 (pl) |
| MX (1) | MX2023005576A (pl) |
| PL (1) | PL4244208T3 (pl) |
| PT (1) | PT4244208T (pl) |
| RS (1) | RS66839B1 (pl) |
| SA (1) | SA523440403B1 (pl) |
| SI (1) | SI4244208T1 (pl) |
| TW (1) | TWI904281B (pl) |
| UA (1) | UA130186C2 (pl) |
| UY (1) | UY39516A (pl) |
| WO (1) | WO2022101412A1 (pl) |
| ZA (1) | ZA202304134B (pl) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| IL313987A (en) | 2021-12-29 | 2024-08-01 | Psy Therapeutics Inc | Inhibiting monoacylglycerol lipase (magl) |
| IL316302A (en) | 2022-05-04 | 2024-12-01 | H Lundbeck As | Crystalline form of 111333-hexafluoropro s-1-pyridazin-3-ylca azaspiro2.5octane-6- as a monoacylglycerol lipase inhibitor |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2429991A (en) | 2005-09-07 | 2007-03-14 | Alan Barrows | Water powered impulsive unit |
| WO2008023720A1 (en) | 2006-08-23 | 2008-02-28 | Astellas Pharma Inc. | Urea compound or salt thereof |
| TW200902007A (en) | 2007-05-25 | 2009-01-16 | Astrazeneca Ab | Spirocyclopropyl piperidine derivatives |
| US20100113465A1 (en) * | 2008-10-30 | 2010-05-06 | Pfizer Inc. | 7-azaspiro[3.5]nonane-7-carboxamide compounds |
| US20120083476A1 (en) | 2009-06-05 | 2012-04-05 | Janssen Pharmaceutica Nv | Heteroaryl-substituted spirocyclic diamine urea modulators of fatty acid amide hydrolase |
| FR2960875B1 (fr) | 2010-06-04 | 2012-12-28 | Sanofi Aventis | Derives de carbamates d'hexafluoroisopropyle, leur preparation et leur application en therapeutique |
| WO2012047703A2 (en) * | 2010-10-04 | 2012-04-12 | Schering Corporation | Cyclopropyl-spiro-piperidines useful as sodium channel blockers |
| MX350788B (es) | 2012-01-06 | 2017-09-13 | Abide Therapeutics Inc | Compuestos de carbamato y preparación y uso de los mismos. |
| DK2820008T3 (en) * | 2012-03-02 | 2017-03-27 | Genentech Inc | AMIDO-SPIROCYCLIC AMIDE AND SULPHONAMIDE DERIVATIVES |
| EP3590940B1 (en) | 2012-09-25 | 2021-06-09 | F. Hoffmann-La Roche AG | Hexahydropyrrolo[3,4-c]pyrrole derivatives and related compounds as autotaxin (atx) inhibitors and as inhibitors of the lysophosphatidic acid (lpa) production for treating e.g. renal diseases |
| MX2015017961A (es) | 2013-07-03 | 2016-10-14 | Abide Therapeutics Inc | Compuestos orgánicos pirrolo-pirrol carbamato y relacionados, composiciones farmacéuticas y usos médicos de los mismos. |
| CR20160496A (es) | 2014-04-04 | 2017-01-02 | X-Rx Inc | Inhibidores espirocíclicos sustituidos de la autotaxina |
| WO2016149401A2 (en) | 2015-03-18 | 2016-09-22 | Abide Therapeutics, Inc. | Piperazine carbamates and methods of making and using same |
| HK1249101A1 (zh) | 2015-07-31 | 2018-10-26 | 辉瑞公司 | 作为magl抑制剂的1，1，1-三氟-3-羟基丙-2-基氨基甲酸酯衍生物及1，1，1-三氟-4-羟基丁-2-基氨基甲酸酯衍生物 |
| JP6790094B2 (ja) | 2015-11-12 | 2020-11-25 | エーエフエーエスシーアイ，インコーポレイテッド | イオンチャネル阻害化合物、医薬製剤および使用 |
| MY194647A (en) | 2016-03-31 | 2022-12-09 | Takeda Pharmaceuticals Co | Heterocyclic compound |
| WO2017197192A1 (en) * | 2016-05-12 | 2017-11-16 | Abide Therapeutics, Inc. | Spirocycle compounds and methods of making and using same |
| JOP20190107A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| JOP20190105A1 (ar) | 2016-11-16 | 2019-05-09 | Lundbeck La Jolla Research Center Inc | مثبطات أحادي أسيل جليسرول ليباز (magl) |
| EP3571202B1 (en) * | 2017-01-23 | 2021-06-30 | Pfizer Inc. | Heterocyclic spiro compounds as magl inhibitors |
| UA126685C2 (uk) | 2017-08-29 | 2023-01-11 | Луннбек Ла-Холья Рісьоч Сенте, Інк. | Сполуки, які є модуляторами magl, і способи їх отримання і застосування |
| JP7177825B2 (ja) | 2017-08-29 | 2022-11-24 | ハー・ルンドベック・アクチエゼルスカベット | スピロ環化合物並びにその作製及び使用方法 |
| IL316302A (en) * | 2022-05-04 | 2024-12-01 | H Lundbeck As | Crystalline form of 111333-hexafluoropro s-1-pyridazin-3-ylca azaspiro2.5octane-6- as a monoacylglycerol lipase inhibitor |
-
2021
- 2021-11-10 TW TW110141858A patent/TWI904281B/zh active
- 2021-11-11 UY UY0001039516A patent/UY39516A/es not_active Application Discontinuation
- 2021-11-11 US US17/524,632 patent/US11434222B2/en active Active
- 2021-11-12 HR HRP20250644TT patent/HRP20250644T1/hr unknown
- 2021-11-12 RS RS20250496A patent/RS66839B1/sr unknown
- 2021-11-12 IL IL301818A patent/IL301818B1/en unknown
- 2021-11-12 PT PT218110187T patent/PT4244208T/pt unknown
- 2021-11-12 WO PCT/EP2021/081522 patent/WO2022101412A1/en not_active Ceased
- 2021-11-12 MX MX2023005576A patent/MX2023005576A/es unknown
- 2021-11-12 MA MA62148A patent/MA62148B1/fr unknown
- 2021-11-12 FI FIEP21811018.7T patent/FI4244208T3/fi active
- 2021-11-12 KR KR1020237015365A patent/KR20230107225A/ko active Pending
- 2021-11-12 SI SI202130311T patent/SI4244208T1/sl unknown
- 2021-11-12 CA CA3196119A patent/CA3196119A1/en active Pending
- 2021-11-12 CN CN202512011225.8A patent/CN121824488A/zh active Pending
- 2021-11-12 DK DK21811018.7T patent/DK4244208T3/da active
- 2021-11-12 GE GEAP202516246A patent/GEAP202516246A/en unknown
- 2021-11-12 AR ARP210103142A patent/AR124057A1/es unknown
- 2021-11-12 CR CR20230203A patent/CR20230203A/es unknown
- 2021-11-12 ES ES21811018T patent/ES3025484T3/es active Active
- 2021-11-12 LT LTEPPCT/EP2021/081522T patent/LT4244208T/lt unknown
- 2021-11-12 PL PL21811018.7T patent/PL4244208T3/pl unknown
- 2021-11-12 US US18/252,611 patent/US20240018120A1/en active Pending
- 2021-11-12 EP EP21811018.7A patent/EP4244208B1/en active Active
- 2021-11-12 HU HUE21811018A patent/HUE071543T2/hu unknown
- 2021-11-12 GE GEAP202116246A patent/GEP20257794B/en unknown
- 2021-11-12 AU AU2021379081A patent/AU2021379081A1/en active Pending
- 2021-11-12 UA UAA202301351A patent/UA130186C2/uk unknown
- 2021-11-12 JP JP2023524567A patent/JP7856644B2/ja active Active
- 2021-11-12 EP EP25166976.8A patent/EP4574150A3/en active Pending
- 2021-11-12 CN CN202180073621.0A patent/CN116547274B/zh active Active
-
2023
- 2023-04-04 ZA ZA2023/04134A patent/ZA202304134B/en unknown
- 2023-04-14 CO CONC2023/0004649A patent/CO2023004649A2/es unknown
- 2023-04-17 SA SA523440403A patent/SA523440403B1/ar unknown
- 2023-05-01 JO JOJO/P/2023/0091A patent/JOP20230091A1/ar unknown
- 2023-05-02 DO DO2023000086A patent/DOP2023000086A/es unknown
- 2023-05-09 CL CL2023001339A patent/CL2023001339A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA53937B1 (fr) | Compositions comprenant des souches bactériennes | |
| MA52288B1 (fr) | Modulateurs d'enzymes de modification de méthyle, compositions et utilisations de ceux-ci | |
| MA43979B1 (fr) | Dérivés de 1h-indazole-3-carboxamide et composés similaires en tant qu'inhibiteurs du facteur d pour le traitement de maladies characterisés par une activité aberrante du système complémentaire, comme p.E. Troubles immunologiques | |
| MA30539B1 (fr) | Derives de piperazinyle utiles dans le traitement de maladies induites par le recepteur gpr38. | |
| MA46665B1 (fr) | Composés de tyrosine tyrosine de peptide cyclique couplés à un anticorps en tant que modulateurs des récepteurs du neuropeptide y | |
| MA43169B1 (fr) | Composés héterocycliques en tant qu' inhibiteurs pi3k-gamma | |
| MA44474B1 (fr) | Inhibiteurs de la ferroportine | |
| MA29444B1 (fr) | Antagonistes npy, preparation et utilisations | |
| MA37762A1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA29639B1 (fr) | Derives de cyclohexylamine isoquinolone en tant qu'inhibiteurs de la rhokinase. | |
| MA40768B1 (fr) | Dérivés d'indole mono ou di-substitué en tant qu'inhibiteurs de réplication du virus de la dengue | |
| TN2014000420A1 (fr) | Derives d'indole et d'indazole qui activent la mpk | |
| MA45598B1 (fr) | Stéroles 24-hydroxylés substitués en position 11 pour le traitement des maladies liées au récepteur nmda | |
| MA67288A1 (fr) | Tubulysines et conjugués tubulysines-protéines | |
| MA35728B1 (fr) | Dérivés de 6,7-dihydro-5h-benzo[7]annulène, leur procédé de préparation, préparations pharmaceutiques les contenant et leur utilisation pour la fabrication de produits pharmaceutiques | |
| MA43052B1 (fr) | Inhibiteurs de la kallicréine plasmatique humaine | |
| MA50406B1 (fr) | Inhibiteurs pyrazole de magl | |
| MA46229A (fr) | Composés d'hétéroaryle carboxamide en tant qu'inhibiteurs de ripk2 | |
| MA35455B1 (fr) | (wo2013045407) dérivés d'estra-1,3,5(10),16-tétraène-3-carboxamide, procédé pour leur fabrication, préparations pharmaceutiques contenant ces substances ainsi que leur utilisation dans la fabrication de médicaments | |
| MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
| MA38694B1 (fr) | Dérivés thérapeutiquement actifs d'estratriène-thiazole à substitution azote en position 17 en tant qu'inhibiteurs de la 17bêta.-hydroxystéroïde déshydrogénase | |
| SA523440403B1 (ar) | Magl مثبط | |
| MA56607A1 (fr) | Méthodes de traitement de troubles dépressifs | |
| MA26732A1 (fr) | Composition pharmaceutique nouvelle comprenant un inhibiteur de nos, et procede pour sa preparation | |
| MA68743B1 (fr) | Composés et compositions pour le traitement d'états associés à l'activité du récepteur de lpa |